Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director | May 01, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.82 · Expires 2036-05-01 | Direct | 48,800 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 48,800 · Balance 48,800 F1: The options were granted pursuant to the Company's non-employee director compensation policy. F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May1, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the Company's non-employee director compensation policy.
F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May1, 2026, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 1, 2026 20:16 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001705904-26-000002 · form4-05012026_080505.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2036-05-01 F1 · security: The options were granted pursuant to the Company's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May1, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 20:15 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001104659-25-094490 · tm2527377-4_4seq1.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2035-09-25 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:34 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104440 · tm2425266-4_4seq1.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:02 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 26,100 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001104659-23-105402 · tm2327241-8_4seq1.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock, par value $0.0001 · 26,100 shares Expires 2033-09-28 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 29, 2022 Filed Oct 1, 2022 01:21 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 23,500 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001104659-22-104777 · tm2227177-3_4seq1.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock, par value $0.0001 · 23,500 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 29, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 60 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · derivative · entry 6 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 60 shares Expires 2022-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F1 · shares: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F1 · derivative.underlying_shares: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 159 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · derivative · entry 5 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 159 shares Expires 2022-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 4,775 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F2 · shares: This option was previously reported as covering 4,775 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F2 · derivative.underlying_shares: This option was previously reported as covering 4,775 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 60 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · derivative · entry 4 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 60 shares Expires 2022-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F1 · shares: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F1 · derivative.underlying_shares: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 60 | $2.40 | $144.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · nonDerivative · entry 3 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 159 | $2.40 | $381.60 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · nonDerivative · entry 2 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 60 | $2.40 | $144.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · nonDerivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:47 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 24,100 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001104659-21-119490 · tm2128463-7_4seq1.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,100 Underlying: Common Stock, par value $0.0001 · 24,100 shares Expires 2031-09-23 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 23, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 2,000 | $11.99 | $23,980.00 |
DisclosureSEC source: 0000899243-20-033630 · doc4.xml · nonDerivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,900 Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 10,150 | $9.91 | $100,586.50 |
DisclosureSEC source: 0000899243-20-031031 · doc4.xml · nonDerivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $10.16, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 22:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 25,500 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0000899243-20-026410 · doc4.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock, par value $0.0001 · 25,500 shares Expires 2030-09-24 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 24, 2020, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 24, 2020 Filed Oct 16, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units ("RSUs") · Derivative | 16,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028536 · doc4.xml · derivative · entry 2 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F2 · derivative.exercise_date: On June 25, 2020, the reporting person was granted 16,850 restricted stock units, which vested in full at the Company's 2020 annual meeting of stockholders on September 24, 2020. F2 · derivative.expiration_date: On June 25, 2020, the reporting person was granted 16,850 restricted stock units, which vested in full at the Company's 2020 annual meeting of stockholders on September 24, 2020. Read SEC document |
| September 24, 2020 Filed Oct 16, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 16,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028536 · doc4.xml · nonDerivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:52 UTC | Altimmune, Inc. ALT · Entity 5349 | ConversionRestricted Stock Units ("RSUs") · Derivative | 16,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017831 · doc4.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,850 Underlying: Common Stock · 16,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F2 · derivative.exercise_date: The RSUs vest in full at the Company's 2020 annual meeting of stockholders, subject to the reporting person's continued service through the vesting date, and have no expiration date. F2 · derivative.expiration_date: The RSUs vest in full at the Company's 2020 annual meeting of stockholders, subject to the reporting person's continued service through the vesting date, and have no expiration date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:18 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001012975-19-000039 · edgar.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The option becomes vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| October 13, 2017 Filed Oct 18, 2017 00:16 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001012975-17-000767 · edgar.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2027-10-13 Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 1,791 | Not disclosed Strike: $0.59 | Not disclosed |
DisclosureSEC source: 0000899243-17-012363 · doc4.xml · derivative · entry 5 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791 Underlying: Common Stock, par value $0.0001 · 1,791 shares Expires 2023-12-31 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 1,791 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012363 · doc4.xml · derivative · entry 4 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791 Underlying: Common Stock, par value $0.0001 · 1,791 shares Expires 2022-12-31 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 1,791 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012363 · doc4.xml · derivative · entry 3 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791 Underlying: Common Stock, par value $0.0001 · 1,791 shares Expires 2022-07-04 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 4,775 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012363 · doc4.xml · derivative · entry 2 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,775 Underlying: Common Stock, par value $0.0001 · 4,775 shares Expires 2022-07-04 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 5,998 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-012363 · doc4.xml · nonDerivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement, the then outstanding shares of Altimmune's capital stock was converted into the right to receive a number of shares of the Issuer's common stock, par value $0.0001 on a 0.749106:1 basis upon the closing of the merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.